Sleep Quality Evolution: Dreem Under CPAP

Evolution of Sleep Quality During the Initiation of Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnea Syndrome: an Exploratory Study

Continuous positive airway pressure (CPAP) has a caricatural effect in reducing nocturnal respiratory abnormalities and improving the micro-and macrostructure of sleep. Studies characterizing the improvement of acute sleep parameters after the initiation of CPAP are limited to one or two nights of polysomnographic recording. This is related to the cost of performing these studies with repeated recordings in the laboratory and to the acceptability by patients to perform multiple nights of recordings.

Investigators currently have powerful and reliable methods allowing us to carry out nights at home in the patient's ecosystem, in real-life conditions. The characterization of sleep parameters by these methods is equivalent to a polysomnographic recording.

These technological innovations will allow us to characterize sleep before the initiation of CPAP treatment during several nights performed at home. Investigators will then be able to characterize the kinetics and stability of the improvement of sleep parameters in patients with obstructive sleep apnea syndrome in whom continuous positive airway pressure is initiated.

These data will be original and will serve as exploratory data to judge whether the objective improvement of sleep parameters in the first weeks of treatment is associated with improvement in sleepiness, quality of life, and compliance with treatment.

Study Overview

• Status: Recruiting
• Conditions: Obstructive Sleep Apnea; Sleep Apnea
• Intervention / Treatment: Device: Deem 3 Headband

Detailed Description

This study aims to evaluate the quality of sleep, principally the deep slow-wave sleep (sleep stage N3) before and after the initiation of continuous positive airway pressure (CPAP) treatment.

70 newly diagnosed patients with OSA requiring CPAP treatment, will be included.

For the study, they will wear the Dreem 3 headband and pulse oximeter at home before initiation of CPAP (for 7 nights) and during the first month of CPAP (for a minimum of 9 nights). They will be also equipped with a glucose sensor and a pedometer during the entire study period before and after CPAP treatment.

Patients will also complete questionnaires about their health status before CPAP treatment (at inclusion) and after one month of treatment

These devices will allow the measurements of different parameters: sleep stages, total sleep time, sleep measures derived from sleep stages, snoring, breathing rate, heart rate head movements, arterial hemoglobin oxygen saturation, pulse rate, continuous subcutaneous glucose level, and physical activity data (average daily steps, average distance walked per day).

This will generate interesting data on the sleep parameters and their evolution during the initiation of the CPAP treatment.

• Study Type: Interventional
• Enrollment (Estimated): 70
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Jean Louis Pépin, MD, PhD; Phone Number: 0033 476 768 766; Email: JPepin@chu-grenoble.fr
• Study Contact Backup: Name: Marie Joyeux-Faure, PharmD, PhD; Email: MJoyeuxfaure@chu-grenoble.fr

Study Locations

• France
  • Grenoble, France
    • Recruiting
    • Grenoble Alpes University Hospital
    • Contact: Jean Louis Pépin, MD, PhD; Phone Number: 0033 476 768 766; Email: JPepin@chu-grenoble.fr
    • Contact: Marie Joyeux-Faure, PharmD, PhD; Email: MJoyeuxfaure@chu-grenoble.fr
    • Contact: Jean Louis Pépin, MD, PhD
    • Contact: Renaud Tamisier, MD,PhD
    • Contact: Rita CHERPEC épouse CLIN, MD,PhD
    • Contact: Marie Destors, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 26 years to 61 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients newly diagnosed with OSA requiring CPAP treatment
• Patients able to use a mobile application on a smartphone or tablet
• Patients with access to a wi-fi internet connection at home
• Patients agreeing to remote monitoring of CPAP compliance data by the home care provider
• Patients who have signed consent to participate in the study
• Subjects affiliated to a social security

Exclusion Criteria:

• Patients already treated for OSA
• Patients treated with a sleep aid (sleeping medications)
• Patients with severe chronic obstructive or restrictive lung disease with or without oxygen
• Patients with unstable cardiovascular disease or severe heart failure requiring hospitalization within the last three months or meeting New York Heart Association criteria, Class III or IV disease
• Subjects listed in articles L1121-5 to L1121-8: pregnant women, feeding and parturients, subjects deprived of liberty by judicial or administrative decision, persons under legal protection
• Persons in a period of exclusion from another study or ongoing participation in a drug study
• Subjects likely, at the investigator's discretion, to be uncooperative or noncompliant with the obligations inherent to participation in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Technological innovations and CPAP; Patients will be equipped with 4 devices: a Dreem 3 Headband, a pulse oximeter, a continuous glucose sensor, and a pedometer. In parallel they will be equipped by the CPAP at home by Icadom.	Device: Deem 3 Headband; The patient will wear the Dreem 3 headband and pulse oximeter at home before initiation of CPAP (for 7 nights) and during a month of treatment (for a minimum of 9 nights), after the initiation of CPAP. He will also wear a glucose sensor and a pedometer during the entire study period before and after CPAP treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of deep slow-wave sleep (sleep stage N3) before and after initiation of continuous positive airway pressure (CPAP) treatment.	Time spent on the deep slow-wave sleep stage (stage N3 sleep), recorded by the Dreem 3 headband, from 7 nights before and 9 nights after initiation of CPAP treatment	7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of the other sleep stages (W, N1, N2 and REM)	Sleep stages (W, N1, N2 and REM) and total sleep time spent in each sleep stage, recorded by the Dreem 3. All the data units are in minutes	7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation
Duration of different sleep times	Sleep parameters recorded by Dreem 3 headband: sleep times (bedtime, total sleep time (TST), sleep onset delay (SOD),time in bed (TIB), time awake after falling asleep (WASO), final wakefulness time)	7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation
The percentage of time while sleeping	Sleep parameter recorded by Dreem 3 headband: sleep efficiency ((TST/TIB) x100)	7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation
The frequences of sleep waves during the NREM sleep stage recorded by Dreem 3 headband	sleep spindle density expressed in Hertz recorded by the EEG sensors	7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation
The frequence of snoring while sleeping recorded by Dreem 3 headband	snoring is expressed in decibel minute recorded by a microphone integrated in the Dreem3	7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation
Respiratory rate measurment recorded by Dreem 3 headband	It is expressed in breathe per minute recorded accelerometer sensor	7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation
Heart rate measurement while sleepingrecorded by Dreem 3 headband	Expressed in beats per minute recorded by accelerometer sensor	7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation
The position of the head changes while sleeping recorded by Dreem 3 headband	Head movements are recorded by an accelerometer sensor in the Dreem 3 Headband	7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation
Evolution of the nocturnal oximetry	Nocturnal oxygen saturation measured by a pulse oximeter	7 nights before CPAP initiation and for a month (minimum 9 nights) after CPAP initiation
Evolution of the subcutaneous glucose level	Continuous subcutaneous glucose level (measured by FreeStyle Libre 2 continuous glucose sensor)	7 nights before CPAP initiation and for a month after CPAP initiation
Evolution of glycemia	Blood glucose level by blood sampling	At inclusion and a month after CPAP initiation
Average daily number of steps	It will be measured by a Garmin Vivofit 3 pedometer expressed in steps/day	7 nights before CPAP initiation and for a month after CPAP initiation
Average distance walked per day	It will be measured by a Garmin Vivofit 3 pedometer expressed in Kilometer	7 nights before CPAP initiation and for a month after CPAP initiation
Sleep quality assessed by Pittsburg questionnaire	The PSQI includes a scoring key for calculating a patient's seven subscores, each of which can range from 0 to 3. The subscores are tallied, yielding a "global" score that can range from 0 to 21. A global score of 5 or more indicates poor sleep quality; the higher the score, the worse the quality.	At inclusion and a month after CPAP initiation
Severity of insomnia measured by the index sverety of insomnia questionnaire	The general ISI score varies between 0 and 28: -7 = No insomnia 8-14 = Sub-clinical insomnia (mild) 15-21 = Clinical insomnia (moderate) 22-28 = Clinical insomnia (severe)	At inclusion and a month after CPAP initiation
Evolution of the somnolence	Epworth Sleepiness Score (ESS): 0 = no chance of dozing or falling asleep; = low chance of falling asleep; = medium chance of falling asleep; = high chance of falling asleep	At inclusion and a month after CPAP initiation
Evolution of the quality of life by the Short Form 36 health survey questionnaire	A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.	At inclusion and a month after CPAP initiation
Evolution of the compliance of CPAP treatment	Collection of average CPAP treatment use (in hours/day) provided by telemonitoring	For a month during CPAP treatment
Evolution of the effectiveness of CPAP treatment	Collection of residual AHI provided by telemonitoring	For a month during CPAP treatment

Collaborators and Investigators

• Sponsor: University Hospital, Grenoble
• Collaborators: AGIR à Dom; Dreem
• Investigators: Principal Investigator: Jean Louis Pépin, MD, PhD, Grenoble Alpes University Hospital (CHUGA)

Study record dates

Study Major Dates

• Study Start (Actual): October 3, 2022
• Primary Completion (Estimated): November 3, 2025
• Study Completion (Estimated): December 3, 2025

Study Registration Dates

• First Submitted: December 1, 2021
• First Submitted That Met QC Criteria: January 5, 2022
• First Posted (Actual): January 20, 2022

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 20, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: Continuous Positive Airway Pressure (CPAP); Technological innovations; Sleep Stages; Dreem Headband
• Additional Relevant MeSH Terms: Nervous System Diseases; Respiratory Tract Diseases; Respiration Disorders; Sleep Wake Disorders; Signs and Symptoms, Respiratory; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Apnea Syndromes; Sleep Apnea, Obstructive; Apnea
• Other Study ID Numbers: 38RC21.0346

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No